Bylvay Disease Interactions
There are 3 disease interactions with Bylvay (odevixibat).
Odevixibat (applies to Bylvay) cirrhosis
Moderate Potential Hazard, Moderate plausibility.
The efficacy and safety of odevixibat in patients with clinically significant portal hypertension and in patients with decompensated cirrhosis have not been established.
Pemigatinib (applies to Bylvay) hepatic dysfunction
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease
The recommended dosage of pemigatinib should be reduced in patients with severe hepatic dysfunction. No dose adjustment is recommended for patients with mild or moderate hepatic impairment.
Pemigatinib (applies to Bylvay) renal dysfunction
Moderate Potential Hazard, Moderate plausibility.
The recommended dosage of pemigatinib should be reduced in patients with severe renal disease. No dose adjustment is recommended for patients with mild or moderate renal impairment, or those patients with end-stage renal disease receiving intermittent hemodialysis.
Switch to professional interaction data
Bylvay drug interactions
There are 28 drug interactions with Bylvay (odevixibat).
Bylvay alcohol/food interactions
There are 2 alcohol/food interactions with Bylvay (odevixibat).
Report options
More about Bylvay (odevixibat)
- Bylvay consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous GI agents
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Livmarli
Livmarli is used to treat Alagille syndrome (ALGS) in people 3 months and older and progressive ...
Maralixibat
Maralixibat systemic is used for cholestatic pruritus in alagille syndrome, cholestatic pruritus in ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
